Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
221
resultados
Última actualización
01/05/2026 [07:09:00]
Resumen de: US20260115138A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Resumen de: US20260116928A1
The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.
Resumen de: US20260115299A1
The present invention relates to calsequestrin-based metal ion reactive particles and their applications. More specifically, the invention concerns calsequestrin-based metal ion reactive particles, which are prepared by combining bioactive substances frequently used in pharmaceuticals and cosmetics with calsequestrin (CSQ) and then reacting them with metal ions. This invention also relates to the use of these particles as drug delivery carriers, pharmaceutical compositions, or vaccines. The metal ion reactive particles according to the present invention can enhance the in vivo and in vitro stability of bioactive substances, prolong their active duration, increase their half-life in the body, and improve antigen delivery efficiency.
Resumen de: US20260115162A1
Composition or association of compounds comprising: a) the active principle docosahexaenoic acid DHA (C22:6 ω-3 C22H32O2 MW 328.488) mixed with all or in part, with: b) hyaluronic acid HA4 tetrasaccharide (C28H44N2O23 MW 776) in nanoparticles c) β-caryophyllene βCP (C15H24 MW 204.35), d) furanoeudesma-1,3-diene FE (C15H18O MW 214.30), e) β-boswellic acid PBA (C30H48O3 MW 456.7). preferably for use in the treatment of nervous diseases in particular neurodegenerative diseases, method for the preparation of such composition or association of compounds and uses thereof.
Resumen de: US20260115316A1
The present invention provides lipid nanoparticles for delivering nucleic acid to spleen tissue that can improve the efficiency of nucleic acid delivery to spleen tissue cells, and a method for delivering nucleic acid to spleen tissue by using same. A lipid nanoparticle for use in delivering a nucleic acid to a spleen tissue, including (A) an ionic lipid represented by the formula (1),(B) an anionic phospholipid or a compound represented by the formula (2),(C) cholesterol, and(D) a dimyristoylglycerol PEG represented by the formula:(definitions of symbols in the formula are as described in the specification), and a method for delivering a nucleic acid to a spleen tissue by using same.
Resumen de: US20260117071A1
Problem To provide: an ICG lipid derivative that can form a lipid-based particle that has an excellent stability and/or can selectively release a drug; and a lipid-based particle containing this ICG lipid derivative.SolutionA lipid-based particle comprising a compound represented by formula (A) below or a pharmaceutically acceptable salt thereof,wherein, R1 and R2 each independently represent —(CH2)k—CONH—R3; R3 represents a group selected from the group consisting of —(CH2)m—OPO3−—CH2—CH(CH2OCOR4)(OCOR5), branched-chain C14 to C40 alkyl, and branched-chain C14 to C40 alkenyl;R4 and R5 each independently represent straight-chain or branched-chain C13 to C21 alkyl or straight-chain or branched-chain C13 to C21 alkenyl;k represents an integer from 2 to 4; andm represents an integer from 2 to 4.
Resumen de: US20260115319A1
Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.
Resumen de: US20260115314A1
The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.
Resumen de: US20260115139A1
Provided are lipids and nanoparticles containing such lipids and a cargo molecule, such as nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The lipids may have the structure of Formula A as defined herein.
Resumen de: US20260115317A1
The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and/or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.
Resumen de: US20260116844A1
The present invention relates to: ionized lipids comprising lipids with a branched structure; a lipid nanoparticle formulation using same; and use thereof. The ionized lipids of the present invention are a biodegradable lipid material with a lipid structure in which a heteroamine structure is branched, and the lipid nanoparticles using the ionized lipids can deliver a nucleic acid drug and the like with high efficiency, and thus can be effectively used in related technical fields such as mRNA vaccines and therapeutic agents.
Resumen de: US20260115221A1
Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.
Resumen de: US20260115251A1
The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
Resumen de: US20260115144A1
Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.
Resumen de: US20260115313A1
An antibody-conjugated liposome, particularly a nanoparticle. The surface of the nanoparticle contains antibodies. The number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, for example, a liposome, can more effectively exert a therapeutic effect on tumor and improve multidrug resistance of tumor, thereby overcoming the technical prejudice that it is commonly considered that the more antibodies on a surface of a liposome, the better the target cell binding effect, and laying a foundation for further clinical development.An antibody-conjugated liposome, particularly a nanoparticle, the surface of which contains antibodies, and the number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, such as a liposome, can more effectively exert a therapeutic effect on tumors and reduce the multidrug resistance of tumors. This overcomes the generally accepted technical bias that more antibodies on the surface of a liposome lead to better binding with target cells, thereby laying the foundation for further clinical development.
Resumen de: WO2026018264A1
The present invention relates to a nanoformulation comprising L-leucyl-L-leucine methyl ester (LLOMe) and a polymer for wound healing, which promotes multiple molecular signaling pathways essential for faster wound healing. The nanoformulation offers faster and improved wound and tissue healing, axon regeneration, antiviral immunity, stem cell proliferation, embryonic development, and anti-aging effects.
Resumen de: EP4480943A1
The present invention concerns a lipid of formula (I), a composition comprising said lipid of formula (I), a process for manufacturing said lipid of formula (I) and/or said composition, the lipid of formula (I) and/or the composition for its use as a medicament, the use of said lipid of formula (I) and/or of said composition as a vector for delivering an active ingredient to subject(s), organ(s), cell(s) and/or tissue(s). a method for transfecting cells with a nucleic acid and/or a protein and/or a peptide and/or a polysaccharide and/or a lipid and/or a small organic or inorganic molecule and/or any type of bioactive molecule using said lipid of formula (I) and/or said composition, transfected cells obtained by said method, and a kit comprising said lipid of formula (I) and/or said composition.
Resumen de: WO2024263721A1
The present disclosure relates to compositions comprising nucleic acid delivery vehicles encoding the estrogen receptor beta (ERβ), and methods of treating and/or preventing diseases or disorders with ERβ dysregulated function.
Resumen de: WO2024263919A2
Described herein is a delivery system and method that can be used to deliver therapeutic compositions to epithelial cells. Provided are lipid nanoparticles comprising an ionizable lipid, a sterol, a phospholipid, and a lipid conjugated to PEG. Also described are novel molecules that can be used for gene editing. Methods include methods for delivering a therapeutic cargo to the airway or epithelium of a subject and/or a method for treating an airway or gastrointestinal disorder in a subject, the method comprising administering: i) a first lipid nanoparticle comprising a surfactant; and ii) a second lipid nanoparticle comprising a therapeutic cargo. Further methods describe a method for delivering a therapeutic cargo to the airway or epithelium of a subject and/or a method for treating an airway or gastrointestinal disorder in a subject, the method comprising administering: a lipid nanoparticle comprising a therapeutic cargo, wherein the lipid nanoparticle comprises a surfactant.
Resumen de: WO2024263729A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Resumen de: WO2024263770A1
The present disclosure relates to lipidoid compounds comprising toll-like receptor (TLR) agonists, lipid nanoparticles (LNPs) comprising the same, and methods of use thereof. In certain embodiments, the LNPs described herein are useful for enhancing the therapeutic and/or prophylactic effect of vaccine compositions.
Resumen de: WO2024259531A1
There is provided a lipid nanoparticle comprising (a) from about 40 to 100 mol % of an ionizable lipid; (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the ionizable lipid is at least one compound of formula (I): or a pharmaceutically acceptable salt thereof. The lipid nanoparticle can comprise a cargo and can be used for delivering a cargo to a cell.
Resumen de: US2024424017A1
0000 A method of inducing expression of aquaporin-4 by providing a bioconjugate having a quantum dot bound to human erythropoietin and contacting human astrocytes with the bioconjugate, which induces expression of aquaporin-4. A composition having a bioconjugate having a quantum dot bound to human erythropoietin. A method of providing a quantum dot and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
Resumen de: WO2024259530A1
A fluid composition having reduced susceptibility to at least one of oxidative spoilage and of microbial spoilage is provided, wherein the fluid composition consists of nanobubbles of gas, and each nanobubble in the fluid composition ranges in size from 1 nanometer to 500 nanometers to reduce the at least one of the oxidative spoilage and of the microbial spoilage. There is also provided a process for reducing a fluid composition susceptibility to at least one of oxidative spoilage and of microbial spoilage which consists of mixing nanobubbles of gas into the fluid composition, and each nanobubble in the fluid composition ranges in size from 1 nanometer to 500 nanometers for reducing the at least one of the oxidative spoilage and of the microbial spoilage.
Nº publicación: EP4731606A1 29/04/2026
Solicitante:
BIONTECH SE [DE]
BioNTech SE
Resumen de: WO2025027089A1
The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.
BOPI
Sede Electrónica
